The aim of this study was to assess the inter- and intrarater reliability of a recently proposed scoring system for temporomandibular disorders (TMD), based upon radiological findings from magnetic resonance imaging (MRI). Patients with clinically suspected uni- or bilateral TMD, and subsequently conducted MRI examination of both temporomandibular joints, were included in this study. MRI data were independently evaluated by two experienced radiologists according to the DLJ scoring system proposed by Wurm et al., which includes assessment of the following categories: articular disk (prefix 'D'), direction of disk luxation (prefix 'L'), and osseous joint alterations (prefix 'J'). 60 patients (49 female and 11 male) were eligible for analysis. No significant differences were found between both observers regarding 'D' and 'L' scores (p = 0.13 and p = 0.59, respectively). Significant differences were found for the assessment of subtle osseous changes ('J0' category: p = 0.041; 'J1' category: p = 0.018). Almost perfect intra- and interrater agreements were found for 'D' and 'L' categories (intrarater and interrater agreements for 'D': κ = 0.92 and κ = 0.84, respectively; intrarater and interrater agreements for 'L': κ = 0.93 and κ = 0.89, respectively). However, the assessment of 'J' categories revealed only moderate interrater agreement (κ = 0.49). The DLJ scoring system based upon MRI findings is feasible for routine clinical TMD assessment, and may help to simplify interdisciplinary communication between radiologists and clinicians.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcms.2021.11.010DOI Listing

Publication Analysis

Top Keywords

scoring system
16
interrater agreements
12
temporomandibular disorders
8
dlj scoring
8
'd' 'l'
8
agreements 'd'
8
intrarater interrater
8
imaging temporomandibular
4
disorders reliability
4
reliability novel
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

EQT Life Sciences Partners, Amsterdam, 1071 DV Amsterdam, Netherlands.

Background: Alzheimer's disease (AD) trials report a high screening failure rate (potentially eligible trial candidates who do not meet inclusion/exclusion criteria during screening) due to multiple factors including stringent eligibility criteria. Here, we report the main reasons for screening failure in the 12-week screening phase of the ongoing evoke (NCT04777396) and evoke+ (NCT04777409) trials of semaglutide in early AD.

Method: Key inclusion criteria were age 55-85 years; mild cognitive impairment due to AD (Clinical Dementia Rating [CDR] global score of 0.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.

Background: Alzheimer disease (AD) is a progressive neurodegenerative disease that is accountable for the leading case of dementia in elder people. Before, only symptomatic treatments are available for AD. Since 2021, two anti-amyloid antibodies aducanumab and lecanemab have been approved by the US Food and Drug Administration.

View Article and Find Full Text PDF

Background: Accumulating evidence suggests that the presynaptic protein α-synuclein (α-syn), is involved in the pathophysiology of AD and elevated in the cerebrospinal fluid (CSF). The role of Natural Killer (NK) cells of the innate immune system in AD has largely been overlooked. In a murine model, depletion of NK cells augmented the accumulation of pathological α-syn.

View Article and Find Full Text PDF

Background: Over 15 million informal caregivers provide assistance to persons living with dementia. Despite increasing emergency department (ED) use within the population, little is known regarding the support required of older adults seeking acute care with varying degrees of cognitive impairment. Our objectives were to quantify the daily care hours that informal caregivers provide to older ED patients with diagnosed dementia, undiagnosed cognitive impairment, and intact cognition.

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

Neurobehavioral Systems, Inc, Berkeley, CA, USA.

Background: Paper-and-pencil neuropsychological tests have traditionally been considered the "gold standard" for clinical testing in AD/ADRD, but they have significant limitations: They are time-consuming, costly to administer, vulnerable to examiner bias and error, and unavailable to some patients due to location, transportation challenges, and cost. Manual tests also fail to comprehensively analyze many aspects of test performance. Computerized neuropsychological test batteries have been developed to address these shortcomings.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!